---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059164"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:18:27.405587+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Q1 net loss $5.7M; FDA approves Mydcombi for mydriasis

## Summary
- FDA approved Mydcombi (tropicamide/phenylephrine) for mydriasis, first product using Optejet delivery system.
- Received FDA feedback on Microline presbyopia candidate providing clear and efficient path forward.
- Entered co-development agreement with Formosa Pharmaceuticals to combine Optejet with APNT nanoparticle platform.
- Q1 net loss $5.7M ($0.15/share) vs $7.3M ($0.24/share) in Q1 2022; operating expenses down to $5.5M.
- Cash and equivalents $18.5M at March 31, 2023; additional $5M available on Avenue Capital credit facility.

## SEC filing metadata
- accession: 0001104659-23-059164
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/0001104659-23-059164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/tm2315261d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059164
- JSON: https://secwatch.observer/filing/0001104659-23-059164.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059164.txt

## Key facts
- Earnings Releases
  HYPERION DEFI, INC. reported first quarter ended March 31, 2023 results: net income $(5.7) million, EPS $(0.15) per share.
  - Period: first quarter ended March 31, 2023
  - Net income: $(5.7) million
  - EPS: $(0.15) per share
  - Result: reported results
  source text: For the first quarter of 2023, net loss was approximately $(5.7) million, or $(0.15) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/0001104659-23-059164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.